.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent clinical data suggests that lenvatinib plus pembrolizumab efficacy extends to difficult-to-treat nonendometrioid endometrial cancers. A retrospective study at Jichi Medical University Hospital evaluated clinical outcomes for patients with recurrent disease. Specifically, researchers examined rare variants like carcinosarcoma and mesonephric-like adenocarcinoma. Although these subtypes often carry a poor prognosis, the combination therapy showed meaningful clinical activity.
The study involved 26 patients, including 11 with nonendometrioid carcinoma. Notably, the objective response rate for the nonendometrioid group reached 33.3%. Furthermore, the disease control rate was exceptionally high at 90.9%. In comparison, the endometrioid group had a response rate of 22.2% and a disease control rate of 100%.
Median progression-free survival was 6.2 months for nonendometrioid types. However, patients with endometrioid histology achieved a longer median survival of 11.5 months. In addition, the median overall survival for nonendometrioid cases was 12.0 months. Consequently, these findings highlight the potential of this regimen in managing aggressive histological variants.
Hypertension was the most frequent adverse event, occurring in 92.3% of patients. Moreover, hypothyroidism affected 65.4% of the cohort. As a result, histology and platinum-free intervals were not identified as independent prognostic factors for survival. Therefore, the treatment benefit remains consistent across various clinical subgroups. Further accumulation of patient data is warranted to validate these results in uncommon histologic types.
Research indicates an objective response rate of 33.3% and a disease control rate of 90.9% for nonendometrioid subtypes, including carcinosarcoma and mesonephric-like adenocarcinoma.
The most common adverse events are hypertension, which affects over 90% of patients, and hypothyroidism, seen in approximately 65% of cases.
Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or as a substitute for professional healthcare guidance. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A study reveals the efficacy of lenvatinib plus pembrolizumab for recurrent nonendometrioid endometrial cancer, showing a 33.3% objective response rate....
6 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
